HRA Pharma Posts Big Rise As Key Brands Grow Double Digits

Paris-based HRA Pharma reported significant sales gains for its key consumer health brands in 2021, helping to lift group turnover by more than 25%. This is likely to be the last set of results posted by HRA as a standalone company with Perrigo optimistic its proposed acquisition of the firm will soon complete.

SC1807_Market Growth_572387551_1200.jpg
• Source: Shutterstock

France’s HRA Pharma recorded a significant rise in sales in 2021 as demand increased for its biggest consumer health brands.

While the privately-held firm did not disclose a full set of results, it did report a 26% rise in group...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

Kenvue Makes CEO Change Months After Critical Activist Investor Made Proxy Play For Board Seat

Thibaut Mongon is out as Kenvue CEO, a post he’s held since J&J spun it out in July 2023, after the firm’s results came under increased investor scrutiny over the past year. The board appointed as interim CEO Kirk Perry, a board member since December who most recently headed technology, data and pre

Perrigo Combines Americas, International Leads Into Global Post In Latest Move To Boost Results

 

Roberto Khoury, Perrigo’s international lead for a year, moves to CCO while his counterpart for the Americas region appointed in September 2023, Catherine "Triona" Schmelter, is leaving with her post eliminated in the firm’s changes.

Acquisitions Help Spain’s Uriach Grow Sales By More Than 50%

 
• By 

European consumer health player Uriach records sales approaching €500m in 2024 after completing acquisitions which took the firm into new markets.

Stada Held Back By Weak Cough & Cold Season

 
• By 

While sales of seasonal products struggled during Q1, Stada pointed to the continuing strength of its underlying Consumer Healthcare portfolio.

More from Business

Over The Counter: How To Balance Access And Equity In Self-Care, With Bayer’s Emese Csoke

HBW Insight speaks to Bayer Consumer Health's global strategy director for regulatory, medical, safety, quality, and compliance Emese Csoke about how least how widening access to self-care solutions can be balanced with equity with regards to affordability.

Lupin Goes For Growth With Indian Consumer Health Spin-Off

 
• By 

With annual sales approaching $20m, LupinLife Consumer Healthcare has ambitious growth plans for the Indian OTC market.

US Tariff Overhang Weighs on Chinese API Exports

 

Chinese API exports to US fell 24% year-on-year to $255m in May, when US and China called a truce in a previously escalating trade war.